Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Galapagos Achieves Milestones in Two Strategic Alliances
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos NV announces achievement of milestones totaling €2.5 million in two of its strategic alliances.
In the alliance with Janssen Pharmaceutica NV (Janssen) in rheumatoid arthritis, Galapagos received a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.
In Galapagos' alliance with GlaxoSmithKline (GSK) in the area of infectious diseases, Galapagos received a €1 million milestone payment. Since initiation of this alliance at the end of 2007, Galapagos has received a total of €6 million under the anti-infectives alliance with GSK.
"Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues," said Onno van de Stolpe, CEO of Galapagos.
In the alliance with Janssen Pharmaceutica NV (Janssen) in rheumatoid arthritis, Galapagos received a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.
In Galapagos' alliance with GlaxoSmithKline (GSK) in the area of infectious diseases, Galapagos received a €1 million milestone payment. Since initiation of this alliance at the end of 2007, Galapagos has received a total of €6 million under the anti-infectives alliance with GSK.
"Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues," said Onno van de Stolpe, CEO of Galapagos.
